CLEVELAND, Dec. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Northside Hospital in Georgia has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy treatment services at its Northside Hospital Cancer Institute in Atlanta.

Northside Hospital Cancer Institute is the largest and most comprehensive cancer network in Georgia. The institute offers more radiation oncology centers and advanced radiation therapy treatment units than any other hospital system in Georgia. Northside's expert, board-certified physicians practicing at multiple locations across Georgia, and its network of over 55 cancer centers, allows patients to receive the most advanced treatments close to home. The MRIdian system will enable the team at the Cancer Institute to offer the latest MR-guided radiation therapy technology to patients seeking cancer treatment for lung, prostate, pancreas, liver cancers, and other small tumors in abdominal and pelvic areas.

"As a leader in cancer care in Georgia, we are excited add the MRIdian system to our treatment services for cancer patients, particularly those patients who may not have had viable treatment options," said Ajaykumar Patel, M.D., Radiation Oncology, Northside Hospital Cancer Institute. "MRIdian will allow us to practice personalized and precision medicine and continue to lead the way with cutting edge technology in the Metro Atlanta Area."
"Expanding MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) with Northside Hospital is a significant milestone for patients in the southeast," said Paul Ziegler, chief commercial officer at ViewRay. "As a premier health provider in Atlanta, we look forward to working with the Northside team on a combined mission to improve the lives of cancer patients."

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable nearby organs-at-risk and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and surrounding healthy tissues, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

Nearly 16,000 patients have been treated with MRIdian. Currently, 46 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.


About ViewRay:
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.

MRI Homepage